Russell Investments Group Ltd. Acquires 16,728 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Russell Investments Group Ltd. raised its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 9.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 200,615 shares of the biopharmaceutical company’s stock after buying an additional 16,728 shares during the period. Russell Investments Group Ltd.’s holdings in Ultragenyx Pharmaceutical were worth $9,593,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. UMB Bank n.a. lifted its position in Ultragenyx Pharmaceutical by 118.8% in the 4th quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 329 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of Ultragenyx Pharmaceutical by 2.2% in the third quarter. Arizona State Retirement System now owns 20,163 shares of the biopharmaceutical company’s stock valued at $719,000 after purchasing an additional 441 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Ultragenyx Pharmaceutical by 38.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,979 shares of the biopharmaceutical company’s stock valued at $95,000 after buying an additional 548 shares during the last quarter. Covestor Ltd grew its holdings in Ultragenyx Pharmaceutical by 392.1% during the third quarter. Covestor Ltd now owns 748 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 596 shares in the last quarter. Finally, Xponance Inc. raised its position in Ultragenyx Pharmaceutical by 6.8% in the 4th quarter. Xponance Inc. now owns 10,162 shares of the biopharmaceutical company’s stock valued at $486,000 after buying an additional 648 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Trading Up 0.6 %

Shares of NASDAQ RARE opened at $43.01 on Tuesday. The stock has a fifty day simple moving average of $47.10 and a two-hundred day simple moving average of $44.29. Ultragenyx Pharmaceutical Inc. has a 1-year low of $31.52 and a 1-year high of $54.98. The firm has a market cap of $3.57 billion, a price-to-earnings ratio of -5.36 and a beta of 0.68.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing the consensus estimate of ($1.72) by ($0.31). Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 421.88%. The firm had revenue of $108.83 million for the quarter, compared to the consensus estimate of $116.03 million. During the same period last year, the company posted ($2.33) earnings per share. Ultragenyx Pharmaceutical’s revenue for the quarter was up 8.3% on a year-over-year basis. Analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.38 EPS for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Matthew K. Fust sold 12,195 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $50.88, for a total transaction of $620,481.60. Following the sale, the director now owns 14,860 shares in the company, valued at $756,076.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 3,756 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $53.76, for a total transaction of $201,922.56. Following the sale, the executive vice president now owns 67,340 shares in the company, valued at $3,620,198.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Matthew K. Fust sold 12,195 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $50.88, for a total value of $620,481.60. Following the sale, the director now owns 14,860 shares in the company, valued at approximately $756,076.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,116 shares of company stock valued at $1,645,983. Company insiders own 6.80% of the company’s stock.

Analyst Upgrades and Downgrades

RARE has been the subject of several recent analyst reports. TD Cowen upped their target price on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Robert W. Baird upped their price objective on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 30th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday. JPMorgan Chase & Co. boosted their target price on Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, March 18th. Finally, Royal Bank of Canada assumed coverage on Ultragenyx Pharmaceutical in a report on Monday, April 22nd. They issued an “outperform” rating and a $77.00 target price for the company. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $87.85.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.